phase 1 trial

Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL

A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.